- Home
- TYGO vs EPIX Comparison
TYGO vs EPIX Comparison
Compare TYGO & EPIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TYGO
- EPIX
- Stock Information
- Founded
- TYGO 2007
- EPIX 2009
- Country
- TYGO United States
- EPIX Canada
- Employees
- TYGO N/A
- EPIX N/A
- Industry
- TYGO Semiconductors
- EPIX Biotechnology: Pharmaceutical Preparations
- Sector
- TYGO Technology
- EPIX Health Care
- Exchange
- TYGO Nasdaq
- EPIX Nasdaq
- Market Cap
- TYGO 86.2M
- EPIX 75.9M
- IPO Year
- TYGO N/A
- EPIX N/A
- Fundamental
- Price
- TYGO $1.32
- EPIX $1.70
- Analyst Decision
- TYGO Strong Buy
- EPIX Hold
- Analyst Count
- TYGO 2
- EPIX 3
- Target Price
- TYGO $3.75
- EPIX $2.00
- AVG Volume (30 Days)
- TYGO 60.4K
- EPIX 54.8K
- Earning Date
- TYGO 08-05-2025
- EPIX 08-04-2025
- Dividend Yield
- TYGO N/A
- EPIX N/A
- EPS Growth
- TYGO N/A
- EPIX N/A
- EPS
- TYGO N/A
- EPIX N/A
- Revenue
- TYGO $63,051,000.00
- EPIX N/A
- Revenue This Year
- TYGO $69.44
- EPIX N/A
- Revenue Next Year
- TYGO $21.75
- EPIX N/A
- P/E Ratio
- TYGO N/A
- EPIX N/A
- Revenue Growth
- TYGO N/A
- EPIX N/A
- 52 Week Low
- TYGO $0.58
- EPIX $1.40
- 52 Week High
- TYGO $1.85
- EPIX $7.88
- Technical
- Relative Strength Index (RSI)
- TYGO 57.95
- EPIX 48.47
- Support Level
- TYGO $1.14
- EPIX $1.60
- Resistance Level
- TYGO $1.56
- EPIX $1.73
- Average True Range (ATR)
- TYGO 0.12
- EPIX 0.05
- MACD
- TYGO -0.01
- EPIX -0.00
- Stochastic Oscillator
- TYGO 44.19
- EPIX 44.44
About TYGO Tigo Energy Inc.
Tigo Energy Inc designs solar power conversion and storage products that provide customers with more choice and flexibility. Its mission is to deliver smart hardware and software solutions that enhance safety, increase energy yield, and lower operating costs of residential, commercial, and utility-scale solar systems. Geographically the company generates revenue from EMEA, Americas, and APAC.
About EPIX ESSA Pharma Inc.
ESSA Pharma Inc is a pharmaceutical company. The company was focused on the development of small-molecule drugs for the treatment of castration-resistant prostate cancer. It was developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival. Currently, the company has terminated its clinical trials and other studies.